2 November 2026 Sydney, Australia

Notice of Initial Substantial Security Holder ("Notice")

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its CHESS Depositary Interests ("CDIs"), a Notice of Initial Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder: John Moore

Date of becoming a Substantial Holder: 30 October 2026

Details of voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):

Class of Securities	Number of CDIs	Person's Votes	Voting Power (1)
Chess Depository Interests	14,491,756	14,491,756	5.58%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power (1)
John A Moore	John A Moore Revocable A/C	14,372,756	5.53%
John A Moore	John A Moore (via custodian account)	119,000	0.05%

(1) Based on 259,855,544 CDIs on issue on issue as outlined in Appendix 2A released to ASX on 30 October 2026.

NYR has provided a copy of this Notice to John A Moore who has confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) (Act), including the number of equity securities or CDIs disclosed in the Notice, being 14,491,756 CDIs, and that these equity securities represent all equity securities held, and to be held under legal agreement, by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.

– ENDS –

About Nyrada Inc

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

Investor, Media & Corporate Enquiries:
Dimitri Burshtein
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.